FITC Anti-Human CD279/PD-1 Antibody[EH12.2H7] (E-AB-F1229C) elabscience

$174.00
In stock
SKU
E-AB-F1229C
SizePrice (USD)
100Tests$174.00
20Tests$66.00
100Tests×2$264.00

Product Details

AbbreCD279/PD-1
SynonymsPD1, PDCD1, Protein PD-1, hPD-1
SwissprotQ15116
ReactivityHuman
HostMouse
ClonalityMonoclonal
CloneEH12.2H7
IsotypeMouse IgG1, κ
Isotype ControlFITC Mouse IgG1, κ Isotype Control[MOPC-21]
ApplicationsFCM
ConjugationFITC
Concentration5 μL/Test
BufferPhosphate buffered solution, pH 7.2, containing 0.09% stabilizer.
Research AreasCancer Biomarkers, Immunology, Inhibitory Molecules
Cellular LocalizationMembrane

Product Description

Conjugation Information: FITC is designed to be excited by the Blue laser (488 nm) and detected using an optical filter centered near 530 nm (e.g., a 525/40 nm bandpass filter).

Background: Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 and PD-L2 are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Storage and Shipping

StorageThis product can be stored at 2-8°C for 24 months. Please protected from prolonged exposure to light and do not freeze.
ShippingIce bag
  1. Astragaloside IV inhibits nasopharyngeal carcinoma progression by inhibiting SATB2/Wnt/PD-L1 pathway and enhancing the killing activity of T cells
    Journal: EUROPEAN JOURNAL OF HISTOCHEMISTRY | Year: 2026 | Impact Factor: 1.900
    DOI: 10.4081/ejh.2026.4540 | Reactivity: Human | Sample Type: huHSC-NCG cell-xenograft
  2. Interleukin-17A facilitates tumor progression via upregulating programmed death ligand-1 expression in hepatocellular carcinoma
    Journal: World Journal of Gastrointestinal Oncology | Year: 2025 | Impact Factor: 2.500
    DOI: 10.4251/wjgo.v17.i1.97831 | Reactivity: Human, Mouse | Sample Type: Hep3B cell,Huh7 cell,HCCLM3 cell,T cell
  3. APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1
    Journal: INTERNATIONAL IMMUNOPHARMACOLOGY | Year: 2024 | Impact Factor: 4.800
    DOI: 10.1016/j.intimp.2024.112523 | Reactivity: Human | Sample Type: HNE2 cell,Human peripheral blood mononuclear cell
  4. P2RX1-blocked neutrophils induce CD8+ T cell dysfunction and affect the immune escape of gastric cancer cells
    Journal: CELLULAR IMMUNOLOGY | Year: 2024 | Impact Factor: 3.700
    DOI: 10.1016/j.cellimm.2024.104901 | Reactivity: Human | Sample Type: CD8+ T cell

Reviews

Write Your Own Review
You're reviewing:FITC Anti-Human CD279/PD-1 Antibody[EH12.2H7] (E-AB-F1229C) elabscience
Your Rating
Copyright © 2025 Biogege, Inc. All rights reserved.